In vitro drug-drug interaction screens for canine veterinary medicines: Evaluation of cytochrome P450 reversible inhibition

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1512-1518

  Aidasani, Divesh ^a   Zaya, Matthew J ^a   Malpas, Phyllis B ^b   Locuson, Charles W ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b ZOETIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIMITOTIC AGENT; ANXIOLYTIC AGENT; BUFURALOL; CEFPODOXIME; CLOMIPRAMINE; CYTOCHROME C OXIDASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B11; CYTOCHROME P450 2C21; CYTOCHROME P450 2C41; CYTOCHROME P450 2D; CYTOCHROME P450 2D15; CYTOCHROME P450 3A; CYTOCHROME P450 3A12; CYTOCHROME P450 3A26; DERACOXIB; DICLOFENAC; KETOCONAZOLE; LOPERAMIDE; METHYLPREDNISOLONE; MIDAZOLAM; PHENACETIN; TEMAZEPAM; UNINDEXED DRUG; VETERINARY DRUG;

ANIMAL CELL; ANIMAL DISEASE; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOG; DRUG APPROVAL; DRUG CROSS REACTIVITY; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME INHIBITION; ENZYME SPECIFICITY; EVALUATION; FEMALE; IC 50; IN VITRO STUDY; LIVER MICROSOME; MALE; NONHUMAN; OFF LABEL DRUG USE; PRIORITY JOURNAL; RISK ASSESSMENT; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG INTERACTIONS; MICROSOMES, LIVER; SUBSTRATE SPECIFICITY; VETERINARY MEDICINE;

CANIS FAMILIARIS; MAMMALIA;

EID: 47949094597     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021196     Document Type: Article

References (29)

1. Blaisdell J, Goldstein JA, and Bai SA (1998) Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26:278-283.
2. Brown HS, Galetin A, Hallifax D, and Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-1050.
3. Cohen LH, Remley MJ, Raunig D, and Vaz AD (2003) In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 31:1005-1015.
4. Evans T and Chapple N (2002) The animal health market. Nat Rev Drug Discov 1:937-938.
5. Foti RS, Wahlstrom JL, and Wienkers LC (2007) The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Dispos 35:185-188.
6. 50. J Biomol Screen 7:373-382.
7. Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, and Court MH (2000) Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica 30:575-588.
8. Huang Z, Roy P, and Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961-972.
9. Kuroha M, Azumano A, Kuze Y, Shimoda M, and Kokue E (2002) Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metab Dispos 30:63-68.
10. Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, and Shou M (2005) Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J Pharmacol Exp Ther 313:518-528.
11. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
12. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
13. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
14. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, and Ohashi K (2007) Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 47:871-876.
15. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, and Schoenhard GL (1999) Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 27:1133-1142.
16. Plumb DC (2005) Plumb's Veterinary Drub Handbook. Blackwell Publishing Professional, Ames, IA.
17. Regmi NL, Abd El-Aty AM, Kubota R, Shah SS, and Shimoda M (2007) Lack of inhibitory effects of several fluoroquinolones on cytochrome P-450 3A activities at clinical dosage in dogs. J Vet Pharmacol Ther 30:37-42.
18. Regmi NL, Abd El-Aty AM, Kuroha M, Nakamura M, and Shimoda M (2005) Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs. J Vet Pharmacol Ther 28:553-557.
19. Riviere JE (2007) The future of veterinary therapeutics: a glimpse towards 2030. Vet J 174:462-471.
20. Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, and Tweedie DJ (1998) Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 357:27-36.
21. Sakamoto K, Kirita S, Baba T, Nakamura Y, Yamazoe Y, Kato R, Takanaka A, and Matsubara T (1995) A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys 319:372-382.
22. Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, and Rushmore TH (2003) Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metab Dispos 31:1161-1169.
23. Simpson BS, Landsberg GM, Reisner IR, Ciribassi JJ, Horwitz D, Houpt KA, Kroll TL, Luescher A, Moffat KS, Douglass G, et al. (2007) Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Vet Ther 8:18-31.
24. Tanaka N, Miyasho T, Shinkyo R, Sakaki T, and Yokota H (2006) cDNA cloning and characterization of feline CYP1A1 and CYP1A2. Life Sci 79:2463-2473.
25. Tanaka N, Shinkyo R, Sakaki T, Kasamastu M, Imaoka S, Funae Y, and Yokota H (2005) Cytochrome P450 2E polymorphism in feline liver. Biochim Biophys Acta 1726:194-205.
26. Trepanier LA (2006) Cytochrome P450 and its role in veterinary drug interactions. Vet Clin North Am Small Anim Pract 36:975-985, v.
27. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, and Pasanen M (2007) Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 2007;37:1367-1377.
28. Venkatakrishnan K and Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449-462.
29. Wren JA, Gossellin J, and Sunderland SJ (2007) Dirlotapide: a review of its properties and role in the management of obesity in dogs. J Vet Pharmacol Ther 30 (Suppl 1):11-16.